7 Implementation
7.1 NHS trusts with responsibility for treating people with recurrent malignant glioma (brain cancer) should enable clinicians to consider the option of using temozolomide as set out in section1.
7.2 Clinicians with responsibility for treating people with recurrent malignant glioma (brain cancer) should review their current practice in line with the guidance set out in section1.
7.3 The patient information attached to this guidance as appendix C can be drafted into local information leaflets as advice for people with recurrent malignant glioma (brain cancer) and those who care for them.
7.4 To enable clinicians to audit their own compliance with this guidance it is recommended that treatment plans are recorded for each patient.
7.5 This information should be incorporated into local audit data recording systems and consideration given (if not already in place) to the establishment of appropriate categories in routine electronic record keeping systems used in hospitals and the multi‑disciplinary groups working in support of people with recurrent malignant glioma (brain cancer).
7.6 Relevant clinical guidelines and protocols linking the multi‑disciplinary working for people with recurrent malignant glioma (brain cancer) should be reviewed in the light of this guidance.
7.7 Prospective clinical audit programmes should record the proportion of treatments adhering to this guidance. Such programmes are likely to be more effective in improving patient care when they form part of the organisation's formal clinical governance arrangements and where they are linked to specific post‑graduate activities.